Lectin Binding Protein Microarray Services
Overview
As a leading supplier in the field of microarrays, CD BioGlyco is committed to designing and developing various effective biological microarray products for non-clinical research and providing corresponding testing services. Our microarray test platform provides a full range of analysis and determination services for the study of lectin-related carbohydrates and glycoproteins to help our global customers conduct relevant research and reduce research costs.
Lectin Binding Protein Profiling
The lectin microarray consists of a set of lectins with unique glycan-binding properties printed on a solid support. The emergence of high-throughput glycomics technology enables lectin microarrays to simultaneously observe a variety of unique binding interactions, which has become the main method for studying glycosylation of entire samples. The most significant advantage of the lectin microarray over the glycan profile analysis method is that it only requires minimal sample preparation without releasing glycans, and can simultaneously quantitatively analyze different types of glycans on the complete biological structure. And these glycans can provide a global view of glycosylation status in their local environment. Lectin microarrays can be used to analyze precise glycosylation in various cells during cell development and differentiation to analyze cellular processes, including cell development and differentiation, cell-to-cell communication, pathogen host identification, and cell surface biomarker identification. In addition, it can quickly assess the real-time changes of surface carbohydrate epitopes and examine the dynamic effects of responses to external stimuli such as bacterial sugars. It can also be applied to the development of specific disease diagnostic biomarkers in clinical related research.
Key Technologies
Our service is built upon the powerful principle of using immobilized lectins to analyze the glycan structures present in a sample. Lectins are a class of proteins that bind specifically to certain sugar structures, acting as highly specific probes for different glycan moieties. Our core technology utilizes a high-density microarray platform where an extensive panel of lectins is spotted onto a solid surface. When a biological sample, such as serum or cell lysate, is applied to the microarray, the glycoproteins present bind to their specific lectin partners. This interaction is then detected and quantified, providing a detailed glycosylation profile of the sample. To complement this, we can integrate the microarray analysis with advanced mass spectrometry (MS) to achieve an even deeper level of detail. This combined approach allows for not only a broad, high-throughput overview of the glycome but also the precise structural identification of individual glycans and their protein-binding sites.
Lectin Arrayed, Precision Delivered: Your Glycan Code Deciphered.
Our microarray detection platform based on lectin microarray technology provides lectin conjugate analysis services. Our service process includes sample preparation, chemical labeling, microarray hybridization, and data analysis and processing. Our service can obtain high-throughput N or O glycan analysis maps from cell lysates or body fluids through lectin microarrays to quantify glycoprotein profiles. It can also be combined with mass spectrometry and other technologies to accurately analyze the structure and content of sugar chains or related glycoproteins bound by lectins. Our microarray service can be used to analyze the information of lectin-binding proteins as well as glycoprotein analysis. Lectin microarrays can be based on precise changes in protein sugar patterns, with minimal sample preparation without the need to release glycans, to ensure the true state of protein glycosylation in the tester's clinical samples. This helps to screen early patients with different types of cancers and correctly reflect some of the molecules in the body fluids of healthy, benign lesions and cancer that can be used as potential biomarkers. These characteristics make lectin microarrays very important for the analysis of precious clinical samples.
Workflow
- Sample Preparation and Glycoprotein Labeling
The process begins with the preparation of your biological samples (e.g., cell lysates or serum). Glycoproteins within the sample are then labeled, typically with a fluorescent dye, to enable detection on the microarray surface. This step ensures a strong and clear signal for subsequent analysis.
- Lectin Array Incubation
The prepared and labeled samples are incubated on our proprietary lectin microarrays. The glycoproteins bind to their specific lectin probes on the array. Our comprehensive panel of lectins ensures a wide-ranging analysis of different glycan structures present in your sample.
- Signal Detection and Data Acquisition
After incubation and washing, the microarray slides are scanned with a high-sensitivity scanner to detect the fluorescent signals from the labeled glycoproteins. The intensity of each spot's signal correlates directly with the amount of a specific glycoprotein-lectin interaction, providing quantitative data.
- Bioinformatics and Data Analysis
The raw data is then processed through our advanced bioinformatics pipeline. Our experts analyze the data to identify and quantify differences in glycosylation patterns between sample groups, providing you with a comprehensive report.
Publication Data
DOI.: 10.1074/mcp.M116.059311
Journal: Molecular & Cellular Proteomics
IF: 5.5
Published: 2016
Results: This research developed the first human lectin microarray containing 60 recombinant human lectins and lectin-like proteins purified from yeast. Unlike conventional plant lectin arrays, this platform specifically targets human glycan recognition. Applied to analyze sperm surface glycosylation, the microarray identified strong binding interactions with galectin-1, -7, -8, GalNAc-T6, and ERGIC-53 (LMAN1). These findings were validated via flow cytometry and fluorescence immunostaining. Crucially, functional assays revealed that galectin-8 binding enhances the acrosome reaction in human sperm—a key fertilization process. Mass spectrometry further showed that galectin-1 interacts with membrane proteins like heat shock protein 90 (HSP90). This human-specific microarray offers a powerful tool for probing mammalian glycosylation mechanisms and their biological impacts.
Advantages
- Our microarray platform allows for the simultaneous analysis of thousands of binding events, which is crucial for the rapid screening of a large number of samples. This is a major improvement over time-consuming, low-throughput methods.
- Our microarrays are optimized for high sensitivity, requiring only small sample volumes, making them suitable for precious biological samples. The reproducible nature of our microarray platforms is a key advantage, ensuring consistent and comparable data across experiments.
- By combining microarray technology with complementary methods like mass spectrometry, we provide both a broad glycan profile and detailed structural information, a combination essential for in-depth scientific discovery.
Application
- Lectin microarrays detect disease-associated glycan alterations (e.g., in cancer, liver fibrosis, and Alzheimer's disease), enabling the discovery of non-invasive biomarkers for early diagnosis and monitoring of pathological progression
- The technology profiles glycans from varied sources, including bacteria, viruses, extracellular vesicles, and clinical samples, uncovering roles in host-pathogen interactions, particle assembly, and disease mechanisms.
- This technology identifies functionally significant cell surface glycan signatures, revealing differences between cell types (e.g., normal vs. cancerous) and tracking glycosylation changes during processes like immune cell differentiation and pathogen-host interactions
Frequently Asked Questions
Associated Services
Lectin binding protein microarray services decode glycan-binding specificities across diverse biological systems—revealing critical interactions in pathogen adhesion, immune regulation, and cancer biomarkers through high-throughput screening of immobilized lectins. To extend this static profiling into dynamic functional studies of glycan-mediated interactions under native membrane conditions, we offer Liquid Glycan Display Array (LiGA). This platform engineers fluidic membranes to mimic physiological cell-surface environments, enabling:
Quantifies multivalent interactions with tunable glycan density and mobility;
Tracks lectin diffusion and clustering on live membranes via single-molecule trajectories;
Measures real-time affinity shifts under shear stress or inhibitor exposure.
CD BioGlyco provides high-quality microarray tools and convenient detection services for studying lectin-related carbohydrate structure and glycoprotein analysis. We have a large and well-equipped team of scientists who are committed to cooperating with researchers from all over the world. By choosing outsourcing testing services, your advantage is that you do not need to consider any other expenses, such as equipment, laboratory space, supervision or management. This convenient method can quickly turn around and provide reliable results, thus saving valuable time and resources. Please contact us for more detailed information.
Reference
- Sun, Y.; et al. A human lectin microarray for sperm surface glycosylation analysis. Molecular & Cellular Proteomics. 2016, 15(9): 2839-2851. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





